Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy

Neuro Oncol. 2018 Jan 10;20(1):4-5. doi: 10.1093/neuonc/nox169.

Authors

Katrin Deumelandt^{1

2}, Michael Platten^{1

2

3}, Katharina Ochs^{1

2}

Affiliations

¹ Department of Neurology and National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany.
² DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Department of Neurology, University Hospital Mannheim, Heidelberg University, Heidelberg, Germany.

No abstract available

Publication types

Comment

MeSH terms

Animals
Glioma
Granulocyte-Macrophage Colony-Stimulating Factor*
Immunotherapy*
Mice
Receptors, OX40
Vaccination

Substances

Receptors, OX40
Granulocyte-Macrophage Colony-Stimulating Factor